Gastroenterology

More global studies on the prevalence of celiac disease are needed outside of the US and Europe.

Several companies are testing live microbiota therapies for C difficile infections.

Diagnosing patients with classic GERD symptoms such as heartburn and regurgitation call for an 8-week trial of empiric proton pump inhibitors once daily prior to a meal.

In a study presented at ACG, investigators focus on quality of life improvements for patients with irritable bowel syndrome.

Only 5 individuals of 195 who received liver transplantation had HCC reoccur more than 3 years following surgery.

Students with IBS were also linked to depression and anxiety symptoms.

There has recently been more community spread of C difficile infections.

Various factors decreased the likelihood of achieving SVR, including male gender, cirrhosis, recent injecting drug use, and previous DAA treatment.

There were no serious adverse events or treatment-related adverse events identified in either treatment group.

Fecal microbiota transplantation recipients did gain weight following the procedure.

Investigators found 11.9% of patients with IBD in a survey were considered vaccine hesitant.

There currently is not an approved treatment for EoE by the US Food and Drug Administration.

There was a significant risk-adjusted trend toward decreasing inpatient mortality from 8.7% in 2010 to 7.4% in 2018 for readmissions within 30 days.

Between 2011-2018, hospital admissions for CDI has decreased dramatically.

Patients with the absence of urgency had significantly greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

ACG represents the first major in-person conference since the COVID-19 pandemic.

Even though COVID-19 infection disproportionately impacts minority patients, there’s no indication that vaccine intention differs depending on race in IBD patients.

This study found that compared with the general population, the prevalence of celiac disease in people with type 1 diabetes mellitus is increased.

Dr. Feuerstadt presented data about RBX2660 during the recent ACG 2021 meeting.

In his lecture, The End of the Beginning: Megatrends in Gastroenterology, William Chey, MD, emphasizes the importance of a multidisciplinary integrated care approach to treating IBS.

An absence of urgency was associated with greater reductions in levels of inflammatory biomarkers C-reactive protein and fecal calprotectin in a cohort of patients treated with mirikizumab.

Approximately 88% of patients treated with SER-109 achieved a sustained clinical response at 8 weeks.

A new study presented at ACG 2021 shows microbiome therapeutic CP101 effective in preventing recurrent CDI by increasing intestinal microbiome diversity.

Patients in the open-label extension of the OASIS study saw increases in Inflammatory Bowel Disease Questionnaire (IBDQ) scores.

PROSE allows patients to report their symptoms of dysphagia in real-time.